Arnaud Bolard graduated in 2011 with the equivalent of a Bachelor of Science degree in Biochemistry from the Université de Franche-Comté, Besançon, France. He achieved the last year of his degree as an exchange student at the University of Portsmouth, UK.
In 2012, Arnaud went on to complete a Master of Science in Molecular and Cellular Physiopathology in Jean-Marc Egly’s laboratory at the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) at the Université de Strasbourg. His master's thesis focused on the identification of new ATF3 direct target genes associated with Purkinje cell degeneration in Cockayne Syndrome. He participated in the characterisation of human induced pluripotent stem cells (hiPSC), and on the establishment of a protocol for directed differentiation of hiPSC into Purkinje neurons.
Following this, Arnaud joined the lab of Patrick Plésiat at the Centre National de Référence (CNR) de la Résistance aux Antibiotiques at the Centre Hospitalier Régional Universitaire (CHRU) de Besançon, where under the supervision of Katy Jeannot, he studied the rapid emergence of colistin-resistance Pseudomonas aeruginosa mutants, as well as the molecular link between colistin resistance and ß-lactams hyper-susceptibility in P. aeruginosa mutants.
Arnaud joined the McCarthy and Gloyn teams at the WTCHG in September 2014. He is currently working in the lab of Dr Ben Davies where he is responsible for assisting other researchers in the team with cutting edge techniques centring on hiPSC culture and genome editing techniques, so as to further probe the molecular mechanisms underlying the development of type 2 diabetes.